Ethical considerations and rationale of the MAKI trial: A multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35weeks

M.O. drs. Blanken; M.M. Rovers; E.A.M. Sanders; L.J. Bont

Ethical considerations and rationale of the MAKI trial: A multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35weeks

Translated title of the contribution: Ethical considerations and rationale of the MAKI trial: A multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35weeks

M.O. drs. Blanken
, M.M. Rovers
, E.A.M. Sanders
, L.J. Bont

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Ethical considerations and rationale of the MAKI trial: A multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35weeks
Original language	Undefined/Unknown
Pages (from-to)	1287-1292
Number of pages	6
Journal	Contemporary Clinical Trials
Volume	33
Issue number	6
Publication status	Published - 2012

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed?term=Ethical%20considerations%20and%20rationale%20of%20the%20MAKI%20trial%3A%20A%20multicenter%20double-blind%20randomized%20placebo-controlled%20trial%20into%20the%20preventive%20effect%20of%20palivizumab%20on%20recurrent%20wheezing%20associated%20with%20respiratory%20syncytial%20virus%20infection%20in%20children%20with%20a%20gestational%20age%20of%2033-35weeks

Cite this

drs. Blanken, M. O., Rovers, M. M., Sanders, E. A. M., & Bont, L. J. (2012). Ethical considerations and rationale of the MAKI trial: A multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35weeks. Contemporary Clinical Trials, 33(6), 1287-1292. http://www.ncbi.nlm.nih.gov/pubmed?term=Ethical%20considerations%20and%20rationale%20of%20the%20MAKI%20trial%3A%20A%20multicenter%20double-blind%20randomized%20placebo-controlled%20trial%20into%20the%20preventive%20effect%20of%20palivizumab%20on%20recurrent%20wheezing%20associated%20with%20respiratory%20syncytial%20virus%20infection%20in%20children%20with%20a%20gestational%20age%20of%2033-35weeks

drs. Blanken, M.O. ; Rovers, M.M. ; Sanders, E.A.M. et al. / Ethical considerations and rationale of the MAKI trial: A multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35weeks. In: Contemporary Clinical Trials. 2012 ; Vol. 33, No. 6. pp. 1287-1292.

@article{228966e56e2b4501adf0bbd2e89057c0,

title = "Ethical considerations and rationale of the MAKI trial: A multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35weeks",

author = "\{drs. Blanken\}, M.O. and M.M. Rovers and E.A.M. Sanders and L.J. Bont",

year = "2012",

language = "Undefined/Unknown",

volume = "33",

pages = "1287--1292",

journal = "Contemporary Clinical Trials",

issn = "1551-7144",

publisher = "Elsevier",

number = "6",

}

drs. Blanken, MO, Rovers, MM, Sanders, EAM & Bont, LJ 2012, 'Ethical considerations and rationale of the MAKI trial: A multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35weeks', Contemporary Clinical Trials, vol. 33, no. 6, pp. 1287-1292. <http://www.ncbi.nlm.nih.gov/pubmed?term=Ethical%20considerations%20and%20rationale%20of%20the%20MAKI%20trial%3A%20A%20multicenter%20double-blind%20randomized%20placebo-controlled%20trial%20into%20the%20preventive%20effect%20of%20palivizumab%20on%20recurrent%20wheezing%20associated%20with%20respiratory%20syncytial%20virus%20infection%20in%20children%20with%20a%20gestational%20age%20of%2033-35weeks>

Ethical considerations and rationale of the MAKI trial: A multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35weeks. / drs. Blanken, M.O.; Rovers, M.M.; Sanders, E.A.M. et al.
In: Contemporary Clinical Trials, Vol. 33, No. 6, 2012, p. 1287-1292.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Ethical considerations and rationale of the MAKI trial: A multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35weeks

AU - drs. Blanken, M.O.

AU - Rovers, M.M.

AU - Sanders, E.A.M.

AU - Bont, L.J.

PY - 2012

Y1 - 2012

M3 - Article

SN - 1551-7144

VL - 33

SP - 1287

EP - 1292

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

IS - 6

ER -

drs. Blanken MO, Rovers MM, Sanders EAM , Bont LJ. Ethical considerations and rationale of the MAKI trial: A multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35weeks. Contemporary Clinical Trials. 2012;33(6):1287-1292.